Cargando…

Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma

OBJECTIVE: This study was designed to determine the safety, pharmacokinetics and biologic effects of a human-mouse chimeric anti-CD20 monoclonal antibody (SCT400) in Chinese patients with CD20-positive B-cell non-Hodgkin's lymphoma (CD20(+) B-cell NHL). SCT400 has an identical amino acid sequen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gui, Lin, Han, Xiaohong, He, Xiaohui, Song, Yuanyuan, Yao, Jiarui, Yang, Jianliang, Liu, Peng, Qin, Yan, Zhang, Shuxiang, Zhang, Weijing, Gai, Wenlin, Xie, Liangzhi, Shi, Yuankai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865612/ https://www.ncbi.nlm.nih.gov/pubmed/27199517 http://dx.doi.org/10.21147/j.issn.1000-9604.2016.02.07

Ejemplares similares

Pre-clinical efficacy of CD20-targeted chimeric antigen receptor T cells for non-Hodgkin's lymphoma
por: Wen, Hairuo, et al.
Publicado: (2022)

Novel CD20 monoclonal antibodies for lymphoma therapy
por: Cang, Shundong, et al.
Publicado: (2012)

Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice
por: Smith, Mitchell R, et al.
Publicado: (2005)

Development of a monoclonal antibody for the detection of anti-canine CD20 chimeric antigen receptor expression on canine CD20 chimeric antigen receptor-transduced T cells
por: SAKAI, Osamu, et al.
Publicado: (2021)

Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin’s lymphoma
por: Shi, Yuankai, et al.
Publicado: (2015)

Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20(+) B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis
por: Luo, Chengxin, et al.
Publicado: (2021)

Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study
por: Zhang, Wen, et al.
Publicado: (2022)

Monoclonal antibodies targeting CD20
por: Chang, Chien-Hsing, et al.
Publicado: (2013)

CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cells
por: Jiang, Shuang, et al.
Publicado: (2016)

CD20 Over-Expression in Hodgkin-Reed-Sternberg Cells of Classical Hodgkin Lymphoma: the Neglected Quest
por: Benharroch, Daniel, et al.
Publicado: (2015)

Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies
por: Dillman, R. O.
Publicado: (2006)

Response to: Monoclonal antibodies targeting CD20
por: Klein, Christian, et al.
Publicado: (2013)

Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies
por: Evers, Mitchell, et al.
Publicado: (2020)

CD3+, CD56+, CD4−, CD8−, CD20−, CD30− Peripheral T-Cell Non-Hodgkin's Lymphoma: A Rare Case Report
por: Jagati, Ashish, et al.
Publicado: (2017)

Growth Inhibition of CD20‐positive B Lymphoma Cell Lines by IDEC‐C2B8 Anti‐CD20 Monoclonal Antibody
por: Taji, Hirohumi, et al.
Publicado: (1998)

Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin’s lymphomas
por: Marchesi, Francesco, et al.
Publicado: (2021)

FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy
por: Pyrzynska, Beata, et al.
Publicado: (2018)

Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group
por: Wada, Naoki, et al.
Publicado: (2009)

Potential therapeutic strategy for non-Hodgkin lymphoma by anti-CD20scFvFc/CD28/CD3zeta gene tranfected T cells
por: Zheng, Yihu, et al.
Publicado: (2010)

Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report
por: Zhang, Wen-ying, et al.
Publicado: (2016)

Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
por: Sang, Wei, et al.
Publicado: (2020)

Ofatumumab: a novel monoclonal anti-CD20 antibody
por: Lin, Thomas S
Publicado: (2010)

Anti-CD20 monoclonal antibodies: reviewing a revolution
por: Casan, J. M. L., et al.
Publicado: (2018)

Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment
por: Tvito, Ariella, et al.
Publicado: (2022)

PB2089: ALGORITHM FOR SEVERE COVID-19 RISK STRATIFICATION DEPENDING MONOCLONAL ANTI-CD20 ANTIBODIES TREATMENT DURATION IN NON-HODGKIN LYMPHOMA PATIENTS.
por: Sychevskaya, K., et al.
Publicado: (2022)

Interaction Kinetics with Transcriptomic and Secretory Responses of CD19 CAR Natural Killer Cell Therapy in CD20 Resistant Non-Hodgkin Lymphoma
por: Ravi, Dashnamoorthy, et al.
Publicado: (2019)

Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response
por: Singh, Vijay, et al.
Publicado: (2015)

CD20 Positive T Cell Lymphoma Involvement of Skin
por: Lee, Ki Yeol, et al.
Publicado: (2011)

Recombinant human thrombopoietin prior to mobilization chemotherapy facilitates platelet recovery in autologous transplantation in patients with lymphoma: Results of a prospective randomized study
por: Mo, Hongnan, et al.
Publicado: (2021)

The predictive significance of CD20 expression in B-cell lymphomas
por: Prevodnik, Veronika Kloboves, et al.
Publicado: (2011)

Diagnosis and treatment of CD20 negative B cell lymphomas
por: Katchi, Tasleem, et al.
Publicado: (2017)

Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment
por: Du, Fanny Huynh, et al.
Publicado: (2017)

Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin
por: Ly, Sophia, et al.
Publicado: (2023)

Anti‐CD20 monoclonal antibody therapy in postpartum women with neurological conditions
por: Anderson, Annika, et al.
Publicado: (2023)

CD20 expression is closely associated with Epstein–Barr virus infection and an inferior survival in nodular sclerosis classical Hodgkin lymphoma
por: Zhao, Xia, et al.
Publicado: (2022)

Preliminary In Vitro Effects of CD8+ T Lymphocyte Specific for the CD20 Alternative Splicing D393-CD20 Peptide Expressed on Burkitt Lymphoma Cells
por: Chegni, Hamid, et al.
Publicado: (2019)

A novel glycosylated anti-CD20 monoclonal antibody from transgenic cattle
por: Zhang, Ran, et al.
Publicado: (2018)

BTK inhibitor combined with anti-PD-1 monoclonal antibody for the treatment of CD20-negative primary central nervous system lymphoma: A case report
por: Feng, Lan, et al.
Publicado: (2022)

Epigenetic regulation of CD44 in Hodgkin and non-Hodgkin lymphoma
por: Eberth, Sonja, et al.
Publicado: (2010)

Establishment of C(20)Mab-11, a novel anti-CD20 monoclonal antibody, for the detection of B cells
por: Furusawa, Yoshikazu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9sr833ouipn532363lr2js1bo2